What does ATLAS really tell us about 'high' dose angiotensin-converting enzyme inhibition in heart failure?

John M. Nicklas, Jay N. Cohn, Bertram Pitt

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations

Abstract

The Assessment of Treatment with Lisinopril and Survival (ATLAS) results have been widely quoted by proponents advocating the use of 'high' doses of angiotensin-converting enzyme (ACE) inhibitors for the treatment of heart failure. In ATLAS, however, the relative benefits of 'high' versus 'low' dose ACE inhibition were small. Intermediate doses of ACE inhibitors proven effective in previous placebo-controlled trials provide benefit that appears likely to equal or exceed the benefit from 'high' dose ACE inhibition. Therefore, we recommend that physicians continue to prescribe ACE inhibitors for patients with heart failure based on the target doses used in the placebo-controlled trials and not on the 'high' dose target used in ATLAS.

Original languageEnglish (US)
Pages (from-to)165-168
Number of pages4
JournalJournal of cardiac failure
Volume6
Issue number2
DOIs
StatePublished - Jun 2000

Fingerprint

Dive into the research topics of 'What does ATLAS really tell us about 'high' dose angiotensin-converting enzyme inhibition in heart failure?'. Together they form a unique fingerprint.

Cite this